- 首頁
- App 分析
- AntiCoagAF
- AntiCoagAF Vs. Cardiac Amyloidosis
AntiCoagAF 與 Cardiac Amyloidosis 使用情況與統計
This application is for medical practitioners who need to quickly review which anticoagulant (including the direct oral anticoagulants (DOACs)) to use to prevent stroke in patients with non-valvular atrial fibrillation (NVAF).
It contains relevant information about warfarin, apixaban, dabigatran, rivaroxaban and edoxaban.
Topics covered include: comparison of anticoagulants, patient information, when anticoagulation is required, risk-benefit issues, when warfarin is appropriate, how to choose the dose of a DOAC, starting or switching between anticoagulants, edoxban information, clinical monitoring, bleeding risks, use of antiplatelet agents in addition to oral anticoagulants, managing ischemic strokes on DOACs, reversing anticoagulation in the event of intracerebral haemorrhage, a Cookcroft-Gault creatinine clearance calculator and peri-operative management information.
Information contained within the application was edited by Dr Bruce Campbell. Coding was by CereScape (www.cerescape.com). It is our aim to keep this information current, and we welcome constructive comments and evidenced updated information. Any profit generated by this application will be used to fund stroke research.
- Apple App Store
- 付費
- 醫療
商店排名
- -
All Cardiac Amyloidosis enthusiasts unite! Here is an app which can simplify staying abreast with the updates on the field and having a pocket guide to diagnosis based on the current data.
Developed solely for educational purposes. The app does not substitute your physician's recommendations. Please refer to your physician for any healthcare related questions or treatment recommendations.
- Apple App Store
- 免費版
- 醫療
商店排名
- -
AntiCoagAF與 Cardiac Amyloidosis 比較排名
比較過去 28 天的 AntiCoagAF 排名趨勢與 Cardiac Amyloidosis
AntiCoagAF- -
排名
各國 AntiCoagAF vs. Cardiac Amyloidosis 排名比較
比較過去 28 天的 AntiCoagAF 排名趨勢與 Cardiac Amyloidosis
無可顯示數據
使用我們的免費試用版,與所有網站進行比較
AntiCoagAF VS.
Cardiac Amyloidosis
1月 17, 2025